Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination
Crossref DOI link: https://doi.org/10.1007/s00210-017-1394-z
Published Online: 2017-06-28
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wetzl, Veronika
Schinner, Elisabeth
Kees, Frieder
Faerber, Lothar
Schlossmann, Jens http://orcid.org/0000-0002-2550-6839
Funding for this research was provided by:
SFB699
Novartis Pharma (DE)
License valid from 2017-06-28